Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Abstract Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously changed second line therapy in NSCLC. However, there are still no reliable biomarkers predicting response and survival in this group of patients. PD-L1 revealed to be a correlating, but no perfect marker. There...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Diego Kauffmann-Guerrero, Kathrin Kahnert, Rosemarie Kiefl, Laura Sellmer, Julia Walter, Jürgen Behr, Amanda Tufman
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/258b0d0ca095449cbb7b82735f688793
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:258b0d0ca095449cbb7b82735f688793
record_format	dspace
spelling	oai:doaj.org-article:258b0d0ca095449cbb7b82735f6887932021-12-02T16:53:20ZSystemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study10.1038/s41598-021-90397-y2045-2322https://doaj.org/article/258b0d0ca095449cbb7b82735f6887932021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90397-yhttps://doaj.org/toc/2045-2322Abstract Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously changed second line therapy in NSCLC. However, there are still no reliable biomarkers predicting response and survival in this group of patients. PD-L1 revealed to be a correlating, but no perfect marker. Therefore, we sought to investigate in this prospective study, whether inflammation status and cytokine profile could serve as additional biomarkers guiding treatment decision for single agent ICIs in NSCLC. 29 stage IV NSCLC patients receiving single agent PD-1 checkpoint-inhibitor in second line were prospectively enrolled. Inflammatory scores and cytokine profiles (IL-6, IL-8, IL-10, IFN-γ and TNFα) have been obtained before treatment and at the time of the first staging. Cytokine profiles were correlated with response and survival. Patients with signs of pre-therapeutic inflammation (elevated, NLR, SII, IL-6, IL-8) showed significantly lower response to ICI treatment and reduced PFS. Contrary, elevated levels of IFN-γ revealed to characterize a subgroup of patients, who significantly benefits from ICI treatment. Furthermore, low systemic inflammation and high levels of IFN-γ characterized patients with long term-response to ICI treatment. Pre-therapeutic assessment of inflammation and cytokine profiles has the ability to predict response and survival in NSCLC patients treated with single agent ICIs.Diego Kauffmann-GuerreroKathrin KahnertRosemarie KieflLaura SellmerJulia WalterJürgen BehrAmanda TufmanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Diego Kauffmann-Guerrero Kathrin Kahnert Rosemarie Kiefl Laura Sellmer Julia Walter Jürgen Behr Amanda Tufman Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
description	Abstract Treatment with single agent immune checkpoint inhibitors (ICIs) has tremendously changed second line therapy in NSCLC. However, there are still no reliable biomarkers predicting response and survival in this group of patients. PD-L1 revealed to be a correlating, but no perfect marker. Therefore, we sought to investigate in this prospective study, whether inflammation status and cytokine profile could serve as additional biomarkers guiding treatment decision for single agent ICIs in NSCLC. 29 stage IV NSCLC patients receiving single agent PD-1 checkpoint-inhibitor in second line were prospectively enrolled. Inflammatory scores and cytokine profiles (IL-6, IL-8, IL-10, IFN-γ and TNFα) have been obtained before treatment and at the time of the first staging. Cytokine profiles were correlated with response and survival. Patients with signs of pre-therapeutic inflammation (elevated, NLR, SII, IL-6, IL-8) showed significantly lower response to ICI treatment and reduced PFS. Contrary, elevated levels of IFN-γ revealed to characterize a subgroup of patients, who significantly benefits from ICI treatment. Furthermore, low systemic inflammation and high levels of IFN-γ characterized patients with long term-response to ICI treatment. Pre-therapeutic assessment of inflammation and cytokine profiles has the ability to predict response and survival in NSCLC patients treated with single agent ICIs.
format	article
author	Diego Kauffmann-Guerrero Kathrin Kahnert Rosemarie Kiefl Laura Sellmer Julia Walter Jürgen Behr Amanda Tufman
author_facet	Diego Kauffmann-Guerrero Kathrin Kahnert Rosemarie Kiefl Laura Sellmer Julia Walter Jürgen Behr Amanda Tufman
author_sort	Diego Kauffmann-Guerrero
title	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
title_short	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
title_full	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
title_fullStr	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
title_full_unstemmed	Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
title_sort	systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in nsclc: a prospective study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/258b0d0ca095449cbb7b82735f688793
work_keys_str_mv	AT diegokauffmannguerrero systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT kathrinkahnert systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT rosemariekiefl systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT laurasellmer systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT juliawalter systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT jurgenbehr systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy AT amandatufman systemicinflammationandproinflammatorycytokineprofilepredictresponsetocheckpointinhibitortreatmentinnsclcaprospectivestudy
_version_	1718382847317770240

Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study

Ejemplares similares